New drug combo shows promise for Tough-to-Treat cancers

NCT ID NCT01116648

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This study tests whether combining two drugs—cediranib (which cuts off a tumor's blood supply) and olaparib (which blocks cancer cell repair)—works better than olaparib alone for people with certain ovarian, fallopian tube, peritoneal, or triple-negative breast cancers that have come back. About 155 adults took part to find the safest dose and see if the combo slows cancer growth longer. The goal is better control, not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube carcinoma fallopian tube neoplasm ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma ovarian serous surface papillary adenocarcinoma primary peritoneal carcinoma primary peritoneal serous adenocarcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FALLOPIAN TUBE CARCINOMA OVARIAN ENDOMETRIOID ADENOCARCINOMA OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA OVARIAN SEROUS ADENOCARCINOMA OVARIAN SEROUS SURFACE PAPILLARY ADENOCARCINOMA PRIMARY PERITONEAL SEROUS ADENOCARCINOMA TRIPLE-NEGATIVE BREAST CARCINOMA

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Cedars-Sinai Medical Center

Los Angeles, California, 90048, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Fort Wayne Medical Oncology and Hematology Inc - Jefferson Boulevard

Fort Wayne, Indiana, 46804, United States
Fort Wayne Medical Oncology and Hematology Inc-Parkview

Fort Wayne, Indiana, 46845, United States
Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287, United States
Massachusetts General Hospital

Charlestown, Massachusetts, 02129, United States
Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States
National Cancer Institute

Rockville, Maryland, 20850, United States
National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States
Newton-Wellesley Hospital

Newton, Massachusetts, 02462, United States
NorthShore University HealthSystem-Evanston Hospital

Evanston, Illinois, 60201, United States
University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637, United States
University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.